IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Core Insights - IGC Pharma has received a new patent for a microdose-based cannabinoid treatment targeting stuttering and Tourette's Syndrome, expanding its portfolio beyond Alzheimer's disease [1] Company Developments - The United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,491,200 to IGC Pharma, which covers the novel treatment [1]